This is the same price previously negotiated with the national healthcare system in France, except that additional discounts and rebates apply in France depending on the volume of sales and the number of treatment failures. Switzerland
In Switzerland, the price is fixed by the government every three years. The price in 2016 was CHF 16,102.50 for 24 pills of 400 mg.

United Kingdom
In 2020, the originator price per course of sofosbuvir was £35,443. In 2013, the price in the United Kingdom was expected to be £35,000 for a 12-weeks course. NHS England established 22 Operational Delivery Networks to roll out delivery, which was approved by the National Institute for Health and Care Excellence in 2015, and proposes to fund 10,000 courses of treatment in 2016–17. Each was given a "run rate" of how many people they were allowed to treat, and this was the NHSs single biggest new treatment investment in 2016. Croatia
As of 2015, sofosbuvir is included on the list of essential medications in Croatia and its cost is fully covered by the Croatian Health Insurance Fund. As a result of negotiations with the manufacturer, only therapies with successful outcome would be paid by the Fund with the rest being covered by the manufacturer. India
In July 2014, Gilead Sciences filed a patent for sofosbuvir in India. If the office of the controller general of patents had granted it, Gilead would have obtained exclusive rights to produce and sell sofosbuvir in the country. However, in January 2015, the Indian Patent Office rejected Gileads application.
In medicine, granulocytosis is the presence of an increased number of granulocytes in the peripheral blood. Often, the word refers to an increased neutrophil granulocyte count (neutrophilia), but granulocytosis formally refers to the combination of neutrophilia, eosinophilia, and basophilia. Leukocytosis refers to an increase in the number of all white blood cells. Causes
Granulocytosis can be a feature of a number of diseases, including:
Infection, especially bacterial
Malignancy, most notably leukemia (it is the main feature of chronic myelogenous leukemia, CML)
Autoimmune disease

Diagnosis
Diagnosis of granulocytosis is usually done by obtaining a complete blood count. Prognostic
In cardiovascular disease, increased white blood cell counts have been shown to indicate a worse prognosis. See also
Agranulocytosis
Bandemia
Complete blood count

References


== External links ==